Alladapt Immunotherapeutics, Inc. announced that it has entered into a term loan agreement for the gross proceeds of $50 million on August 30, 2022. The transaction will include participation from new investor Hercules Capital, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.16 USD | +0.94% | -0.93% | +8.94% |
Apr. 03 | KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. for $100 million. | CI |
Mar. 26 | Bluebird bio to Restate Financial Statements; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.94% | 2.91B | |
+31.41% | 12.02B | |
+1.97% | 1.41B | |
-10.72% | 1.22B | |
-2.48% | 594M | |
+46.95% | 567M | |
-22.19% | 511M | |
-4.17% | 492M | |
+36.49% | 495M | |
+5.84% | 304M |
- Stock Market
- Equities
- HTGC Stock
- News Hercules Capital, Inc.
- Alladapt Immunotherapeutics, Inc. announced that it expects to receive $50 million in funding